Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows.
Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the figure set to more than double to £60-£65mln for the full-year.
